Trial Profile
A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2008 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2006 New trial record.